Type 1 diabetes often appears suddenly, but research has shown that immune changes can be detected before classic symptoms. That has made early screening a more important discussion for families, especially families with a close relative who has type 1 diabetes.
Quick summary
CDC now has public guidance on screening for type 1 diabetes. ADA Standards of Care describe confirmed multiple islet autoantibodies as high risk and recommend referral to specialized centers for staging, education, and consideration of prevention trials or approved treatments.
Key takeaways
- Screening looks for diabetes-related autoantibodies, not ordinary type 2 diabetes risk.
- One positive autoantibody usually needs follow-up, while two or more confirmed autoantibodies carry higher risk.
- Early screening does not guarantee prevention, but it may reduce surprise diagnosis and help families plan.
- Families should discuss emotional readiness, follow-up access, costs, and what they would do with results before testing.
What screening checks
Type 1 diabetes screening usually checks blood for islet autoantibodies, which are immune markers linked with type 1 diabetes risk. CDC explains that one confirmed autoantibody means a person is at risk, and that two or more diabetes-related autoantibodies should be repeated to confirm the result. This is different from checking A1C alone or using an adult type 2 diabetes risk quiz.
Who may be offered screening
TrialNet offers risk screening for eligible relatives of people with type 1 diabetes. CDC and ADA guidance also reflect a growing interest in broader screening discussions. Eligibility, insurance coverage, confirmatory testing, and follow-up pathways vary. Families should ask whether testing is part of a research program, routine care, or a specialist referral.
Why early knowledge can help
Knowing that a child is at increased risk may help families learn symptoms earlier, avoid delayed diagnosis, monitor glucose changes, and consider prevention studies or approved treatment options when appropriate. ADA Standards of Care mention referral for staging, education, and consideration of prevention trials or approved treatments such as teplizumab for eligible people. This does not mean every child with a marker needs medication.
What families should weigh
Screening can bring anxiety, uncertainty, repeat testing, travel, cost, and hard conversations. A negative test does not remove all future risk. A positive test is not the same as a diagnosis requiring insulin. Families should ask who will explain results, how often testing repeats, what symptoms to watch for, and whether mental health support is available.
What to ask your care team
- Is my child eligible for type 1 diabetes autoantibody screening through TrialNet or clinical care?
- If a result is positive, who confirms it and explains stage, risk, and follow-up?
- What symptoms of type 1 diabetes and DKA should we watch for while waiting?
- Would screening results change our monitoring, education, specialist referral, or prevention-treatment options?
Practical takeaway
Early type 1 diabetes screening can be useful for some families, but the value depends on careful counseling, confirmatory testing, and a clear follow-up plan.
Safety note
Seek urgent care for excessive thirst, frequent urination, weight loss, vomiting, abdominal pain, deep or rapid breathing, fruity breath, confusion, or a child who appears very ill, because these can be signs of diabetic ketoacidosis. This information is general education and is not a substitute for medical care.
Source summary
- CDC: Screening for type 1 diabetes. Public guidance on autoantibody screening, confirmed results, and follow-up. Source
- ADA Standards of Care 2026: Diagnosis and classification. Professional recommendations on autoantibodies, staging, referral, and prevention options. Source
- TrialNet: Pathway to Prevention. Risk screening program for eligible relatives and people with prior positive autoantibody testing. Source
- NIDDK: Type 1 diabetes. Patient resource on type 1 diabetes symptoms, causes, diagnosis, and treatment. Source